EU-OPENSCREEN DRIVE

STRUCTURE AND PARTNERS

 

Medicinal Chemistry Consultants

Denmark:

  • Mads H Clausen, mhc@kemi.dtu.dk, Danmarks Tekniske Universitet, Fragment design and synthesis, NMR Screening, hit-to-lead chemistry.

Germany:

  • Marc Nazaré, nazare@fmp-berlin.de, Research Institute for Molecular Pharmacology in the Forschungsverbund Berlin e.V.,FBDD, fragment growing, fragment merging, fragment linking. Scaffold hopping and scaffold hybridization.Hit-triage, structure-activity-relationships and chemical optimization of small molecule modulators.

Latvia:

  • Aigars Jirgensons, aigars@osi.lv, Latvian Institute of Organic Synthesis, Serine protease, aspartic protease, cysteine protease, kinase, and PLP dependent enzyme inhibitors; GPCR, NMDA, and AMPA receptor ligands,  hit-to-lead development, lead optimization; anti-bacterial, anti-malarial, CNS, anti-cancer drug discovery.

Spain:

  • Ana Martinez, ana.martinez@csic.es, Consejo Superior de Investigaciones, Heterocyclic molecules, CNS, BBB, protein kinase inhibitors, small chemical probes, neurodegenerative diseases, neurological disorders.
  • Carmen Gil, carmen.gil@csic.es, Consejo Superior de Investigaciones Científicas, Drug design, heterocyclic molecules, infectious diseases, protein kinase inhibitors, phosphodiesterase inhibitors, protein-protein interaction, ADME properties.